Literature DB >> 32547197

Surgical Compliance and Survival Outcomes for Patients with Stage T1-2 Non-Small-Cell Lung Cancer.

Siben Wang1, Weipu Mao2, Yi Wang3, Xiuquan Shi4, Wei Wang3, Lili Dai3, Wenping Zhang1.   

Abstract

INTRODUCTION: Our aim was to determine the relationship between surgical compliance and survival outcomes in patients with stage T1-2 non-small-cell lung cancer (NSCLC).
METHODS: Patients with T1-2 NSCLC who were diagnosed between 2004 and 2015 were identified from the SEER database. Multivariate logistic regression was used to analyse factors associated with surgical compliance. Kaplan-Meier curves and Cox regression were used to analyse the effects of surgical compliance on overall survival (OS) and cancer-specific survival (CSS).
RESULTS: Of the 221,704 eligible T1-2 NSCLC patients, 106,668 patients recommended surgery. Among them, 99,672 (93.4%) patients were surgical compliance group, and 6996 (6.6%) were surgical noncompliance group. Poor surgical compliance was associated with earlier diagnosis time, old age, male, black race, unmarried status, main bronchus site, poor grade/stage, and lower household income. Patients' compliance was an independent prognostic factor for OS and CSS of T1-2 NSCLC patients. Multivariate Cox regression showed that surgical noncompliance individuals showed lower OS (hazard ratio [HR] 2.494; 95% confidence interval [CI] 2.423-2.566, p < 0.001) and lower CSS (HR 2.877; 95% CI 2.782-2.974, p < 0.001) compared with surgical compliance patients. In addition, results in the non-surgical group were observed to be similar to those of the surgical noncompliance group.
CONCLUSION: We found that patients' compliance was an independent prognostic factor for survival in T1-2 NSCLC patients. Poor surgical compliance was associated with earlier diagnosis time, old age, male, black race, unmarried status, main bronchus site, poor grade/stage, and lower household income.
© 2020 Wang et al.

Entities:  

Keywords:  SEER; non-small-cell lung cancer; surgical compliance; survival outcome

Year:  2020        PMID: 32547197      PMCID: PMC7245446          DOI: 10.2147/CMAR.S238819

Source DB:  PubMed          Journal:  Cancer Manag Res        ISSN: 1179-1322            Impact factor:   3.989


Introduction

Lung cancer is the second most common malignant tumour in the United States. In 2018, the number of newly diagnosed cases of lung cancer ranked second among new malignant tumours both in men and women, and the number of deaths in malignant tumour both in male and female ranked first.1 The most common histological subtype of lung cancer is non-small-cell lung cancer (NSCLC), accounting for about 85%,2 of which lung adenocarcinoma and lung squamous cell carcinoma are the most common subtypes.3 NSCLC is an invasive subtype with high mortality, although great progress has been made in early diagnosis and treatment, there were still many cases diagnosed as advanced and with poor prognosis.4 The treatment of NSCLC includes surgery, chemotherapy, radiotherapy and drug therapy.5–8 For patients with early NSCLC, surgical treatment is the preferred method and the only radical treatment.9 For some patients with stage IIIB and IV metastatic solitary lesions, palliative surgical resection or surgery-based comprehensive treatment can also be given.10 Systemic chemotherapy is the first consideration for patients with advanced NSCLC.11 Although great progress has been made in the diagnosis and treatment of lung cancer in recent years, the current treatment situation of lung cancer was still not optimistic, and the overall 5-year survival rate was still low. Many studies have analyzed the related factors affecting the survival and prognosis of NSCLC patients, such as tobacco prevalence, sex, age, TNM stage and histopathological classification.12,13 In addition, the choice of treatment regimen and patient’s compliance are also prognostic factors in patients with NSCLC. Jayia14 found in a retrospective study that compliance can improve the prognosis of patients with lung cancer. In our study, we tried to identify factors related to surgical incompliance in patients with T1-2 NSCLC, so that clinicians could better intervene.

Methods

The data presented in our study were retrieved from the Surveillance Epidemiology and End Results (SEER) database, which funded by the National Cancer Institute. The SEER database covers approximately 28% of the US population and includes demographic information and cancer characteristics, such as diagnosis age, year of diagnosis, race, marital status, insurance status, income status, primary tumour location, tumour grade and stage, histological type, tumor-node-metastasis (TNM) stage,15 treatment modality and survival time.16 The SEER*Stat software (version 8.3.5; SEER 18 Regs Custom Data (with additional treatment field), Nov 2017 Sub (1973–2015 varying) database) was used in this study, we identified 223,933 T1-2 NSCLC patients between January 1, 2004, and December 31, 2015. Exclusion criteria in our study were as follows: (a) unknown survival time (n=238); (b) patients under 18 years of age (n=30); (c) unknown income (n=14); (d) unknown laterality (n=723); (e) unsure whether to undergo surgery (n=1224). Finally, we left 221,704 eligible patients diagnosed with T1-2 NSCLC. Variable definition information about diagnostic age, year of diagnosis, sex, race, marital status, primary site, median household income, tumour grade, N stage, SEER stage and survival time can be found in the SEER database. Overall survival (OS) and cancer-specific survival (CSS) were the primary endpoints of the study. We divide the diagnostic year into three parts: Group 1: 2004–2007, Group 2: 2008–2011, and Group 3: 2012–2015. We stratify the diagnostic age using X-tile software. The age of diagnosis was divided into three levels: <72 years, 72–79 years, >79 years (). For the marital status, patients are divided into “Married group”, “Unmarried group” and “Unknown marital status group”. Unmarried patients include “Single”, “Separated”, “Divorced” and “Widowed”. Grade was defined by the following codes: well-differentiated (Grade 1); moderately differentiated (Grade II); poorly differentiated (Grade III); undifferentiated (Grade IV) and unknown grade. For the SEER stage, limited to the lung or bronchial tree with no regional lymph node expansion or distant metastasis was defined as localized; ipsilateral regional lymph node and/or regional extension is defined as the regional; distant was defined as metastasis to the contralateral thoracic or distant lymph nodes, malignant pericardium or pleural effusion, extension to areas such as the heart, spine, abdomen, contralateral lung, skeletal muscle and skin. Chi-square analysis was performed to assess clinical characteristics associated with patient compliance. Univariate and multivariate Cox regression models were performed to estimate hazard ratios (HR) and 95% confidence interval (CI) to analyse independent prognostic factors associated with OS and CSS in T1-2 NSCLC patients. The Kaplan–Meier curves were used to estimate OS and CSS in different groups. 1:1 propensity score matching (PSM) was to reduce the selection bias of baseline variables between groups, including age, sex, race, marital status, primary site, grade, N stage, SEER stage and median household income variables. The optimal diagnostic age stratification boundary was found by using X-tile software v3.6.1 (Yale University, New Haven, USA). The Social Science Software Statistics Package (version 24.0; SPSS, Chicago, USA) was used for all statistical analyses. A P value of ≤0.05 was considered statistically significant.

Results

Demographic and Clinical Characteristics of the T1-2 NSCLC Patients

Our study cohort included 221,704 patients with T1-2 NSCLC, of whom 106,668 were recommended for surgery and the remaining 115,036 for non-surgical treatment. Of the patients recommended for surgical treatment, 99,672 (93.4%) underwent surgery and 6996 (6.6%) did not. Table 1 shows the correlation between surgical compliance and clinicopathological features in patients with T1-2 NSCLC. We can conclude that the non-compliance of surgery gradually decreased over time. Chi-square test showed that there were significant differences in surgical compliance among some variables, including the year of diagnosis, diagnosis age, sex, race, marital status, primary site, tumour grade, N stage, SEER staging and median household income (All p < 0.001). We found that older patients (>79 years old), distant patients and low-income (Q2) patients were more likely to refuse surgery, while younger patients (<72 years old), localized patients and high-income (Q4) patients were more likely to receive surgical treatment.
Table 1

Characteristics for T1-2 NSCLC Patients in Our Study

CharacteristicAll PatientsSurgical Compliance GroupSurgical Noncompliance GroupP value
N. (%)N. (%)N. (%)
Total106,66899,672 (93.4)6996 (6.6)
Year of diagnosis<0.001
 2004–200735,664 (33.4)32,905 (33.0)2759 (39.4)
 2008–201136,573 (34.3)34,153 (34.2)2420 (34.6)
 2012–201534,431 (32.3)32,614 (32.7)1817 (26.0)
Age at diagnosis<0.001
 <72 years63,556 (59.6)60,503 (60.7)3053 (43.6)
 72–79 years29,800 (27.9)27,754 (27.8)2046 (29.2)
 >79 years13,312 (12.5)11,415 (11.5)1897 (27.1)
Sex<0.001
 Male51,801 (48.6)48,062 (48.2)3739 (53.4)
 Female54,867 (51.4)51,610 (51.8)3257 (46.6)
Race<0.001
 White90,572 (84.9)84,979 (85.3)5593 (79.9)
 Black9291 (8.7)8325 (8.4)966 (13.8)
 Others6805 (6.4)6368 (6.4)437 (6.2)
Marital status<0.001
 Yes60,311 (56.5)57,263 (57.5)3048 (43.6)
 No42,275 (39.6)38,719 (38.8)3556 (50.8)
 Unknown4082 (3.8)3690 (3.7)392 (4.6)
Primary site<0.001
 Main bronchus746 (0.7)582 (0.6)164 (2.3)
 Upper lobe62,232 (58.3)58,218 (58.4)4014 (57.4)
 Middle lobe5782 (5.4)5431 (5.4)351 (5.0)
 Lower lobe35,092 (32.9)32,948 (33.1)2144 (30.6)
 Overlapping1208 (1.1)1163 (1.2)45 (0.6)
 Lung, NOS1608 (1.5)1330 (1.3)278 (4.0)
Grade<0.001
 Grade I15,413 (14.4)14,991 (15.0)422 (6.0)
 Grade II42,573 (39.9)41,486 (41.6)1087 (15.5)
 Grade III34,619 (32.5)32,854 (33.0)1765 (25.2)
 Grade IV2065 (1.9)1960 (2.0)105 (1.5)
 Unknown11,998 (11.2)8381 (8.4)3617 (51.7)
N stage<0.001
 N081,200 (76.1)77,383 (77.6)3817 (54.6)
 N111,942 (11.2)11,381 (11.4)561 (8.0)
 N211,947 (11.2)10,085 (10.1)1862 (26.6)
 N3882 (0.8)415 (0.4)467 (6.7)
 NX697 (0.7)408 (0.4)289 (4.1)
SEER stage<0.001
 Localized62,353 (58.5)59,362 (59.6)2991 (42.8)
 Regional39,085 (36.6)37,119 (37.2)1966 (28.1)
 Distant5230 (4.9)3191 (3.2)2039 (29.1)
Median household income<0.001
 Q123,337 (21.9)21,814 (21.9)1523 (21.8)
 Q227,340 (25.6)25,215 (25.3)2125 (30.4)
 Q326,154 (24.5)24,298 (24.4)1856 (26.5)
 Q429,837 (28.0)28,345 (28.4)1492 (21.3)

Abbreviations: NSCLC, non-small-cell lung cancer; AJCC, American Joint Committee on Cancer; percentages may not total 100 because of rounding; Grade I, well differentiated; Grade II, moderately differentiated; Grade III, poorly differentiated; Grade IV, undifferentiated; median household income categorized into equally proportioned quartiles.

Characteristics for T1-2 NSCLC Patients in Our Study Abbreviations: NSCLC, non-small-cell lung cancer; AJCC, American Joint Committee on Cancer; percentages may not total 100 because of rounding; Grade I, well differentiated; Grade II, moderately differentiated; Grade III, poorly differentiated; Grade IV, undifferentiated; median household income categorized into equally proportioned quartiles. In addition, we also analyzed the clinicopathological characteristics of surgical noncompliance group and non-surgical group used chi-square test (). We found that in addition to sex, the year of diagnosis, age at diagnosis, race, marital status, primary site, tumour grade, N stage, SEER stage and median household income were significantly different between the two groups (All p < 0.001).

Surgical Compliance-Related Factors

Through multivariable logistic regression, we explore variables related to surgical compliance in patients with T1-2 NSCLC (Figure 1). Patients who were diagnosed recently (2012–2015: odds ratio [OR] 0.802; 95% confidence interval [CI] 0.748–0.860, p < 0.001), female (OR 0.766; 95% CI 0.723–0.812, p < 0.001), lower lobe primary site (OR 0.427; 95% CI 0.340–0.537, p < 0.001), higher income (Q4: OR 0.702; 95% CI 0.645–0.763, p < 0.001)  were more likely to follow surgical treatment.( Older (>79 years: OR 4.374; 95% CI 4.069–4.701, p < 0.001), black race (OR 1.747; 95% CI 1.603–1.904, p < 0.001), unmarried (OR 1.724; 95% CI 1.624–1.830, p < 0.001), grade IV stage (OR 1.358; 95% CI 1.078–1.711, p = 0.009) and distant stage (OR 10.464; 95% CI 9.664–11.329, p < 0.001) were related to poor compliance.
Figure 1

Forest plot of multivariable logistic analyses of surgical noncompliance adjusted by the year of diagnosis, age at diagnosis, sex, race, marital status, primary site, tumour grade, SEER stage and median household income. The black squares on the transverse lines represent the odds ratio (OR), and the transverse lines represent 95% CI. Median household income categorized into equally proportioned quartiles.

Forest plot of multivariable logistic analyses of surgical noncompliance adjusted by the year of diagnosis, age at diagnosis, sex, race, marital status, primary site, tumour grade, SEER stage and median household income. The black squares on the transverse lines represent the odds ratio (OR), and the transverse lines represent 95% CI. Median household income categorized into equally proportioned quartiles.

Identification of Prognostic Factors for OS and CSS in T1-2 NSCLC Patients

In our study, Kaplan–Meier curve was used to analyze the influence of surgical compliance on OS and CSS of T1-2 NSCLC patients (Figure 2). We can find that patients with surgical compliance survived longer than patients with poor compliance and the non-surgical groups. Univariate and multivariate Cox regression were used to analyze the factors associated with OS and CSS in patients with T1-2 NSCLC. As shown in Tables 2 and 3, age at diagnosis, sex, race, marital status, primary site, tumour grade, N stage, SEER stage, patients’ compliance and median household income were factors that affect the OS and CSS in patients with T1-2 NSCLC. Multivariate Cox regression showed surgical noncompliance (vs surgical compliance; HR = 2.494, 95% CI 2.423–2.566, p < 0.001), non-surgical (vs surgical compliance; HR = 2.725, 95% CI 2.686–2.765, p < 0.001) were associated with OS (Figure 3). Similarly, in terms of CSS, multivariate Cox regression analysis also indicated patients’ compliance was an independent prognostic factor for T1-2 NSCLC patients (surgical noncompliance vs surgical compliance; HR = 2.877, 95% CI 2.782–2.974, p < 0.001; non-surgical vs surgical compliance; HR = 3.086, 95% CI 3.033–3.140, p < 0.001) (). In addition, poor surgical compliance patients and non-surgical patients have a similarly poor OS and CSS.
Figure 2

Kaplan–Meier survival curves according to patients’ compliance (surgical compliance, surgical noncompliance, and non-surgical) in patients with T1-2 NSCLC. (A), Overall survival (OS); (B), cancer-specific survival (CSS).

Table 2

Univariate and Multivariate Analysis of Overall Survival (OS) Rates

CharacteristicUnivariate AnalysisMultivariate Analysis
Hazard Ratio (95% CI)P valueHazard Ratio (95% CI)P value
Age at Diagnosis
 <72 yearsReferenceReference
 72–79 years1.239 (1.224–1.254)<0.0011.319 (1.303–1.335)<0.001
 >79 years1.621 (1.599–1.643)<0.0011.565 (1.543–1.588)<0.001
Sex
 MaleReferenceReference
 Female0.733 (0.725–0.741)<0.0010.754 (0.746–0.762)<0.001
Race
 WhiteReferenceReference
 Black1.128 (1.109–1.146)<0.0010.971 (0.954–0.987)0.001
 Others0.837 (0.818–0.857)<0.0010.802 (0.784–0.821)<0.001
Marital Status
 YesReferenceReference
 No1.167 (1.154–1.179)<0.0011.170 (1.157–1.183)<0.001
 Unknown1.024 (0.996–1.054)0.0961.045 (1.015–1.075)<0.001
Primary Site
 Main bronchusReferenceReference
 Upper lobe0.476 (0.461–0.491)<0.0010.767 (0.744–0.792)<0.001
 Middle lobe0.469 (0.451–0.487)<0.0010.796 (0.766–0.827)<0.001
 Lower lobe0.497 (0.481–0.513)<0.0010.842 (0.815–0.869)<0.001
 Overlapping0.498 (0.468–0.530)<0.0010.952 (0.894–1.013)0.121
 Lung, NOS0.869 (0.834–0.905)<0.0010.993 (0.953–1.034)0.718
Grade
 Grade IReferenceReference
 Grade II1.544 (1.506–1.582)<0.0011.389 (1.355–1.424)<0.001
 Grade III2.380 (2.323–2.438)<0.0011.641 (1.601–1.682)<0.001
 Grade IV2.493 (2.387–2.603)<0.0011.755 (1.680–1.833)<0.001
 Unknown3.592 (3.508–3.679)<0.0011.471 (1.436–1.508)<0.001
N Stage
 N0ReferenceReference
 N11.574 (1.546–1.602)<0.0011.189 (1.164–1.214)<0.001
 N22.577 (2.546–2.608)<0.0011.288 (1.268–1.309)<0.001
 N33.091 (3.031–3.152)<0.0011.034 (1.008–1.061)<0.001
 NX3.259 (3.152–3.369)<0.0011.370 (1.323–1.419)<0.001
SEER Stage
 LocalizedReferenceReference
 Regional1.620 (1.599–1.642)<0.0011.446 (1.427–1.466)<0.001
 Distant4.616 (4.556–4.677)<0.0012.719 (2.679–2.759)<0.001
Patients’ Compliance
 Surgical complianceReferenceReference
 Surgical noncompliance3.361 (3.269–3.456)<0.0012.494 (2.423–2.566)<0.001
 Non-surgical4.234 (4.184–4.284)<0.0012.725 (2.686–2.765)<0.001
Median Household Income
 Q1ReferenceReference
 Q20.869 (0.857–0.882)<0.0010.916 (0.903–0.930)<0.001
 Q30.825 (0.813–0.837)<0.0010.874 (0.861–0.887)<0.001
 Q40.761 (0.750–0.773)<0.0010.831 (0.819–0.844)<0.001

Abbreviations: OS, overall survival; AJCC, American Joint Committee on Cancer; Grade I, well differentiated; Grade II, moderately differentiated; Grade III, poorly differentiated; Grade IV, undifferentiated; median household income categorized into equally proportioned quartiles.

Table 3

Univariate and Multivariate Analysis of Cancer-Specific Survival (CSS) Rates

CharacteristicUnivariate AnalysisMultivariate Analysis
Hazard Ratio (95% CI)P valueHazard Ratio (95% CI)P value
Age at Diagnosis
 < 72 yearsReferenceReference
 72–79 years1.124 (1.108–1.140)<0.0011.225 (1.208–1.243)<0.001
 > 79 years1.432 (1.409–1.455)<0.0011.425 (1.402–1.449)<0.001
Sex
 MaleReferenceReference
 Female0.746 (0.737–0.755)<0.0010.783 (0.773–0.792)<0.001
 Race
 WhiteReferenceReference
 Black1.129 (1.107–1.151)<0.0010.940 (0.922–0.959)<0.001
 Others0.871 (0.849–0.895)<0.0010.812 (0.791–0.834)<0.001
Marital Status
 YesReferenceReference
 No1.143 (1.129–1.157)<0.0011.147 (1.133–1.162)<0.001
 Unknown0.969 (0.937–1.002)0.0660.996 (0.963–1.030)0.810
Primary Site
 Main bronchusReferenceReference
 Upper lobe0.431 (0.417–0.446)<0.0010.743 (0.718–0.769)<0.001
 Middle lobe0.431 (0.413–0.450)<0.0010.777 (0.744–0.811)<0.001
 Lower lobe0.449 (0.433–0.465)<0.0010.824 (0.795–0.853)<0.001
 Overlapping0.491 (0.458–0.526)<0.0011.011 (0.943–1.084)0.701
Lung, NOS0.840 (0.804–0.879)<0.0010.981 (0.938–1.026)0.422
Grade
 Grade IReferenceReference
 Grade II1.692 (1.640–1.746)<0.0011.451 (1.406–1.497)<0.001
 Grade III2.879 (2.793–2.967)<0.0011.780 (1.726–1.836)<0.001
 Grade IV3.076 (2.922–3.239)<0.0011.938 (1.840–2.041)<0.001
 Unknown4.456 (4.324–4.591)<0.0011.565 (1.517–1.614)<0.001
N Stage
 N0ReferenceReference
 N11.900 (1.861–1.939)<0.0011.265 (1.236–1.295)<0.001
 N23.262 (3.217–3.308)<0.0011.386 (1.361–1.411)<0.001
 N33.991 (3.907–4.078)<0.0011.123 (1.093–1.155)<0.001
 NX3.905 (3.762–4.054)<0.0011.450 (1.393–1.508)<0.001
SEER Stage
 LocalizedReferenceReference
 Regional2.060 (2.027–2.094)<0.0011.797 (1.768–1.827)<0.001
 Distant6.507 (6.406–6.610)<0.0013.569 (3.507–3.631)<0.001
Patients’ Compliance
 Surgical complianceReferenceReference
 Surgical noncompliance4.014 (3.886–4.145)<0.0012.877 (2.782–2.974)<0.001
 Non-surgical5.226 (5.152–5.302)<0.0013.086 (3.033–3.140)<0.001
Median Household Income
 Q1ReferenceReference
 Q20.876 (0.861–0.890)<0.0010.933 (0.918–0.949)<0.001
 Q30.809 (0.795–0.823)<0.0010.867 (0.853–0.882)<0.001
 Q40.753 (0.740–0.765)<0.0010.831 (0.817–0.845)<0.001

Abbreviations: CSS, cancer-specific survival; AJCC, American Joint Committee on Cancer; Grade I, well differentiated; Grade II, moderately differentiated; Grade III, poorly differentiated; Grade IV, undifferentiated; median household income categorized into equally proportioned quartiles.

Figure 3

Forest plot of multivariable Cox analyses of overall survival (OS) adjusted by the year of diagnosis, age at diagnosis, sex, race, marital status, primary site, tumour grade, SEER stage, patients’ compliance and median household income. The black squares on the transverse lines represent the hazard ratio (HR), and the transverse lines represent 95% CI. Median household income categorized into equally proportioned quartiles.

Univariate and Multivariate Analysis of Overall Survival (OS) Rates Abbreviations: OS, overall survival; AJCC, American Joint Committee on Cancer; Grade I, well differentiated; Grade II, moderately differentiated; Grade III, poorly differentiated; Grade IV, undifferentiated; median household income categorized into equally proportioned quartiles. Univariate and Multivariate Analysis of Cancer-Specific Survival (CSS) Rates Abbreviations: CSS, cancer-specific survival; AJCC, American Joint Committee on Cancer; Grade I, well differentiated; Grade II, moderately differentiated; Grade III, poorly differentiated; Grade IV, undifferentiated; median household income categorized into equally proportioned quartiles. Kaplan–Meier survival curves according to patients’ compliance (surgical compliance, surgical noncompliance, and non-surgical) in patients with T1-2 NSCLC. (A), Overall survival (OS); (B), cancer-specific survival (CSS). Forest plot of multivariable Cox analyses of overall survival (OS) adjusted by the year of diagnosis, age at diagnosis, sex, race, marital status, primary site, tumour grade, SEER stage, patients’ compliance and median household income. The black squares on the transverse lines represent the hazard ratio (HR), and the transverse lines represent 95% CI. Median household income categorized into equally proportioned quartiles.

Subgroup Analysis for Evaluating the Effect of Marital Status on OS and CSS Based on SEER Stage and Grade

Multivariate Cox regression analysis showed that diagnostic age and household income were closely related to the survival of patients. Based on age at diagnosis and household income, we further discussed the differences between surgical compliance and prognosis among the subgroup of T1-2 NSCLC patients (Table 4). We found that for OS and CSS, surgical compliance remained an independent prognostic factor for three age subgroups and four income subgroups (Figures 4 and 5). In each subgroup, the survival rate of patients in the surgical compliance group was still significantly higher than in the other two groups, and the survival of patients in the surgical noncompliance group was slightly higher than that in the non-surgical group.
Table 4

Subgroup Analyses Stratified by Diagnosis Age and Household Income for Overall Survival (OS) and Cancer-Specific Survival (CSS)

CharacteristicOSCSS
Hazard Ratio (95% CI)P valueHazard Ratio (95% CI)P value
<72 Years
 Surgical complianceReferenceReference
 Surgical noncompliance2.708 (2.593–2.828)<0.0012.962 (2.821–3.111)<0.001
 Non-surgical2.929 (2.869–2.991)<0.0013.157 (3.082–2.235)<0.001
72–79 Years
 Surgical complianceReferenceReference
 Surgical noncompliance2.449 (2.323–2.581)<0.0012.904 (2.731–3.088)<0.001
 Non-surgical2.634 (2.566–2.705)<0.0013.090 (2.992–3.192)<0.001
>79 Years
 Surgical complianceReferenceReference
 Surgical noncompliance2.123 (2.004–2.249)<0.0012.629 (2.453–2.817)<0.001
 Non-surgical2.362 (2.286–2.440)<0.0012.854 (2.738–2.975)<0.001
Q1
 Surgical complianceReferenceReference
 Surgical noncompliance2.496 (2.348–2.652)<0.0012.914 (2.717–3.126)<0.001
 Non-surgical2.638 (2.564–2.713)<0.0013.046 (2.944–3.151)<0.001
Q2
 Surgical complianceReferenceReference
 Surgical noncompliance2.517 (2.389–2.653)<0.0012.895 (2.726–3.075)<0.001
 Non-surgical2.776 (2.699–2.856)<0.0013.162 (3.057–3.271)<0.001
Q3
 Surgical complianceReferenceReference
 Surgical noncompliance2.464 (2.327–2.609)<0.0012.842 (2.659–3.038)<0.001
 Non-surgical2.688 (2.608–2.771)<0.0013.020 (2.912–3.133)<0.001
Q4
 Surgical complianceReferenceReference
 Surgical noncompliance2.497 (2.346–2.657)<0.0012.872 (2.672–3.086)<0.001
 Non-surgical2.807 (2.725–2.891)<0.0013.108 (2.999–3.220)<0.001

Abbreviations: OS, overall survival; CSS, cancer-specific survival; median household income categorized into equally proportioned quartiles.

Figure 4

Overall survival (OS) and cancer-specific survival (CSS) curves of T1-2 NSCLC patients according to different diagnosis age. (A and B), OS and CSS in under 72 years patients. (C and D), OS and CSS in 72–79 years patients. (E and F), OS and CSS in over 79 years patients.

Figure 5

Overall survival (OS) and cancer-specific survival (CSS) curves of T1-2 NSCLC patients according to different household income. (A and B), OS and CSS in Q1 income patients. (C and D), OS and CSS in Q2 income patients. (E and F), OS and CSS in Q3 income patients. (G and H), OS and CSS in Q4 income patients.

Subgroup Analyses Stratified by Diagnosis Age and Household Income for Overall Survival (OS) and Cancer-Specific Survival (CSS) Abbreviations: OS, overall survival; CSS, cancer-specific survival; median household income categorized into equally proportioned quartiles. Overall survival (OS) and cancer-specific survival (CSS) curves of T1-2 NSCLC patients according to different diagnosis age. (A and B), OS and CSS in under 72 years patients. (C and D), OS and CSS in 72–79 years patients. (E and F), OS and CSS in over 79 years patients. Overall survival (OS) and cancer-specific survival (CSS) curves of T1-2 NSCLC patients according to different household income. (A and B), OS and CSS in Q1 income patients. (C and D), OS and CSS in Q2 income patients. (E and F), OS and CSS in Q3 income patients. (G and H), OS and CSS in Q4 income patients.

Discussion

Our study first used a large, population-based database to explore the impact of surgical compliance on T1-2 NSCLC patients, and found that surgical compliance was an independent prognostic factor for OS and CSS in T1-2 NSCLC patients. Our study showed that poor surgical compliance was associated with earlier diagnosis time, old age, male, black race, unmarried status, main bronchus site, poor grade/stage and lower household income. As expected, survival analysis showed that the prognosis of the surgical noncompliance group was significantly worse than that of the surgical compliance group. We also analyzed the survival of the patients in the non-surgical group and found that the survival of the patients in the surgical noncompliance group was similar to that in the non-surgical group. Although the proportion of patients with surgical noncompliance was decreasing by years, the number of non-surgical patients was still increasing, and the health status of these patients shall not be ignored. Surgical compliance has a great impact on the survival of cancer patients. Liu17 found that there was a correlation between surgical compliance and the prognosis of gastric cancer, and the survival rate of gastric cancer patients with poor surgical compliance was lower. Adesunkanmi18 surveyed 212 Nigerian breast cancer patients and found that compliance was associated with prognosis, and most of the patients died or lost follow-up within 1 year of diagnosis. Adham19 found that survival was associated with treatment compliance in patients with nasopharyngeal carcinoma in Indonesia. In our study, logistic regression showed that age was associated with surgical compliance. The risk of death increased with age, and surgical compliance remained an independent risk factor for OS and CSS in T1-2 NSCLC patients after diagnosis age stratification. This may be due to the poor physical fitness of elderly patients, suffering from a variety of complications before surgery. This may lead to more conservative treatments and poor compliance in older patients.20 Surgical treatment of lung cancer in elderly patients is associated with many complications.21 However, some studies have shown that there was no significant difference in postoperative complications and 5-year survival rates between the old group (≥75 years old) and the young group (<75 years old).22 Household income was also associated with patient compliance. First of all, the income level was an important predictor of survival time in patients with lung cancer.23 One study suggests that socioeconomic barriers can pose a major challenge to the success of lung cancer screening programs in safety net hospitals, and income levels can affect compliance with screening follow-up.24 In addition, the level of income will affect the use of chemotherapy in patients with II–IV NSCLC.25 Good financial condition is the guarantee of active treatment, and patients with higher household income may be more likely to receive treatment and prolong their survival time.26 Home-based interventions can achieve the highest patient compliance and improve patient’s physical health or clinical symptoms.27,28 Many studies have shown that marital status was an independent prognostic factor for the survival of a variety of cancers, including breast cancer, penis cancer, gastric cancer and colorectal cancer, and unmarried patients have a higher risk of death.29–32 Our study found that marital status was an influential factor in surgical compliance, and married patients were more likely to receive surgical treatment. We speculate that the better prognosis of married patients may be partly due to good surgical compliance. We grouped surgical noncompliance patients and non-surgical patients into a group. After 1:1 PSM with surgical compliance patients, a total of 99,096 patients were included in the study. We performed Kaplan–Meier curve analysis of all patients and found that surgical treatment alone can obtain the best median OS and CSS in surgical compliance patients (); for patients who have not received surgery or surgical noncompliance, radiotherapy can obtain the best median OS and CSS (). Additionally, we also found that tumour grade and stage were also closely related to surgical noncompliance in patients with T1-2 NSCLC. This may be because patients with advanced stage of the tumour have distant metastasis or more complications at the time of diagnosis, the therapeutic effect was poor, and the patient may be less likely to undergo surgery, resulting in poor compliance with the operation. Moreover, the type of insurance was also an independent factor affecting lung cancer patient survival. Tantraworasin33 studied 102,733 lung cancer patients between 2007 and 2013 and found that Asian patients with uninsured or Medicaid-covered were less likely to receive surgery, resulting in a shorter OS. As far as we know, this is the first SEER database-based study to focus on the surgical compliance of T1-2 NSCLC patients, but there are limitations to be recognized in this study. First, this study is a retrospective study with obvious limitations. Second, the lack of information on the physical condition and complications of patients, both of which are prognostic factors for surgical compliance. In addition, it was unclear whether the surgical noncompliance group patients used other treatments, such as chemotherapy, radiotherapy or targeted therapy.

Conclusions

In our study, we found that patients’ compliance was an independent prognostic factor for survival in T1-2 NSCLC patients. Good surgical compliance had better survival, while poor surgical compliance and non-surgical patients have similarly poor OS and CSS. Poor surgical compliance was associated with earlier diagnosis time, old age, male, black race, unmarried status, main bronchus site, poor grade/stage, and lower household income.
  33 in total

1.  Cancer statistics, 2018.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-01-04       Impact factor: 508.702

2.  Initial surgical experience following implementation of lung cancer screening at an urban safety net hospital.

Authors:  Juan A Muñoz-Largacha; Katrina A Steiling; Hasmeena Kathuria; Marjory Charlot; Carmel Fitzgerald; Kei Suzuki; Virginia R Litle
Journal:  J Thorac Cardiovasc Surg       Date:  2018-02-09       Impact factor: 5.209

3.  Demographic disparities in patterns of care and survival outcomes for patients with resected gastric adenocarcinoma.

Authors:  Alexander M Stessin; David L Sherr
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-02       Impact factor: 4.254

4.  Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan.

Authors:  Y Ohe; Y Ohashi; K Kubota; T Tamura; K Nakagawa; S Negoro; Y Nishiwaki; N Saijo; Y Ariyoshi; M Fukuoka
Journal:  Ann Oncol       Date:  2006-11-01       Impact factor: 32.976

5.  Feasibility and effectiveness of a home-based exercise training program before lung resection surgery.

Authors:  Valerie Coats; François Maltais; Sébastien Simard; Eric Fréchette; Lise Tremblay; Fernanda Ribeiro; Didier Saey
Journal:  Can Respir J       Date:  2013 Mar-Apr       Impact factor: 2.409

6.  [Assessment of surgery for patients older than 75 years of age with lung cancer].

Authors:  Yasumi Maze; Hironori Tenpaku; Tomoaki Sato
Journal:  Kyobu Geka       Date:  2006-02

7.  Surgical Compliance and Outcomes in Gastric Cancer: a population-based cohort study.

Authors:  Guihua Liu; Ming Xu; Tingting Gao; Lingying Xu; Peijun Zeng; Haiying Bo; Fang Li; Wei Zhang; Zhengting Wang
Journal:  J Cancer       Date:  2019-02-02       Impact factor: 4.207

Review 8.  Role of cytokines in combinatorial immunotherapeutics of non-small cell lung cancer through systems perspective.

Authors:  Pragya Misra; Shailza Singh
Journal:  Cancer Med       Date:  2019-04-17       Impact factor: 4.452

9.  Current status of cancer care for young patients with nasopharyngeal carcinoma in Jakarta, Indonesia.

Authors:  Marlinda Adham; Sharon D Stoker; Maarten A Wildeman; Lisnawati Rachmadi; Soehartati Gondhowiardjo; Djumhana Atmakusumah; Djayadiman Gatot; Renske Fles; Astrid E Greijer; Bambang Hermani; Jaap M Middeldorp; I Bing Tan
Journal:  PLoS One       Date:  2014-07-14       Impact factor: 3.240

Review 10.  Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer.

Authors:  Shuhang Wang; Shundong Cang; Delong Liu
Journal:  J Hematol Oncol       Date:  2016-04-12       Impact factor: 17.388

View more
  1 in total

1.  Nomogram for predicting the overall survival of patients with early-onset prostate cancer: A population-based retrospective study.

Authors:  Yongtao Hu; Qiao Qi; Yongshun Zheng; Haoran Wang; Jun Zhou; Zongyao Hao; Jialin Meng; Chaozhao Liang
Journal:  Cancer Med       Date:  2022-03-23       Impact factor: 4.711

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.